Table 3

Clinical data for the study population (n = 49) at baseline, 15, and 30 weeks.

Baseline

median (range)

15 weeks

median (range)

15-0 weeks

difference median (range)

P value

30 weeks

median (range)

30 to 0 weeks

difference

median

(range)

P value

Pain threshold kPa

202.8 (105.9-380.5)

189.9 (112.2-305.3)

-9.6 (-102.1-75.6)

0.040

194.3 (107.6-472.3)

-8.8 (-165.2-108.5)

0.608

Pain

0 to 100

71 (7-98)

65.5 (3-99)

-5 (-40-35)

0.052

67 (14-95)

-2 (-39-53)

0.365

6MWT

m

518 (381-660)

566 (418-689

25.1 (-77-164.5)

< 0.001

555 (367.5-661)

15.5 (-150.5-145)

0.009

IGF-1

ng/ml

4.2 (0-35.7)

3.0 (0-33.8)

-0.2 (-31.6-28.7)

0.085

2.7 (0-10.9)

-0.7 (-31.2-1.7)

0.004

IGFB3

ng/ml

1,549.4 (2,69.5-3,288.3)

1,634 (182.4-2,967.3)

-57.5 (-1,551.7-1,846.6)

0.889

1,795.4 (98.3-4,156.7)

272.9 (-1,563-2,821.8)

0.413

Bjersing et al. Arthritis Research & Therapy 2012 14:R162   doi:10.1186/ar3902